ZimVie Announces Publication of a Study Supporting the Benefits of Its Implant Surface Technologies
Rhea-AI Summary
ZimVie Inc. (NASDAQ: ZIMV) announced the publication of a scientific study in the Journal of Biomedical Materials Research demonstrating the advantages of their dental implant surface technology. The study compared ZimVie's T3® PRO and TSX® Implants' dual acid-etched coronal surface technology with other leading implant brands.
The research identified a critical threshold roughness for dental implants, below which bacterial adhesion remains similar to smooth machined surfaces. ZimVie's implants' coronal surfaces, DAE and Osseotite®, are engineered around this threshold, showing bacterial adhesion levels comparable to machined surfaces while maintaining crestal bone levels similar to rougher surfaces.
The findings suggest that ZimVie's implants may help reduce the risk of peri-implant infections compared to other commercial implants, addressing the growing concern of peri-implant mucositis and peri-implantitis in dental implantology.
Positive
- Surface technology demonstrates lower risk of peri-implant infections
- Implants achieve optimal balance between bacterial resistance and bone maintenance
- Scientific validation published in leading journal supports product effectiveness
Negative
- None.
News Market Reaction – ZIMV
In the trading session that priced this news, ZIMV declined 2.41%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Data confirms ZimVie implants meet critical roughness criteria advantageous for long-term peri-implant health
PALM BEACH GARDENS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced the publication of a detailed scientific study demonstrating the surface texture of ZimVie’s premium implants may help to lower the risk of peri-implant infections when compared to other commercially available implants.
The study, titled “The Role of Implant Coronal Surface Properties on Early Adhesion of Streptococcus Oralis—An In Vitro Comparative Study,” has been published in the Journal of Biomedical Materials Research, a leading journal in the field of biological and medical sciences. The study evaluated the innovative dual acid-etched coronal surface technology of ZimVie’s T3® PRO and TSX® Implants against other leading implant brands.
In dental implantology, rough surfaces at the top of the implant, designed to maintain crestal bone levels, may also promote bacterial adhesion. This potentially leads to soft tissue inflammation and peri-implant bone loss, jeopardizing long-term implant success. The new data reveals a critical threshold roughness, above which bacterial adhesion increases significantly, while below that, bacterial adhesion profiles remain comparable to smooth machined surfaces. ZimVie’s implants’ coronal surfaces, DAE and Osseotite®, have been engineered around this threshold. These surfaces not only exhibit bacterial adhesion levels comparable to machined surfaces but also demonstrate crestal bone maintenance akin to rougher surfaces.*
“The prevalence of peri-implant mucositis (inflammation) and peri-implantitis has been on the rise in recent decades,” said Hai Bo Wen, Research Director at ZimVie. “We have always been committed to the highest standards of quality and patient safety and are proud that ZimVie’s Contemporary Hybrid Surface technologies have demonstrated success in helping mitigate this concern in today’s dental implantology field.”
About TSX Implants
Launched in 2022, TSX Implants are designed for immediate extraction and standard loading protocols as well as placement predictability and primary stability in soft and dense bone. The Implant incorporates features with more than two decades of real-world, clinical data to deliver peri-implant health, crestal bone maintenance, long-term osseointegration, and prosthetic stability,* including the Contemporary Hybrid Surface combination with coronal DAE. Integrated with ZimVie’s end-to-end digital workflows and engineered with surgical and restorative versatility, the TSX Implant furthers ZimVie’s commitment to simplify procedures and optimize practice protocols.
About T3 PRO Implants
Launched in 2022, the T3 PRO Implant’s advanced design delivers high primary stability and allows for immediate function. T3 PRO has a hybrid surface featuring the proprietary Osseotite surface on the implant collar, as well as a rougher grit-blasted implant body. Not only have multiple long-term, independent clinical studies on the proprietary Osseotite surface demonstrated safety and performance,* they have also demonstrated the effect of this surface in preserving crestal bone. This Contemporary Hybrid Surface of T3 PRO along with the optional integrated platform switching design has also been shown to provide early and long-term peri-implant bone support.
* References on file at ZimVie.
About ZimVie
ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.
Media Contact Information:
ZimVie
Grace Flowers • Grace.Flowers@ZimVie.com
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Webb Campbell • Webb@gilmartinir.com
